公开(公告)号：US20240230974A9

公开(公告)日：2024-07-11

申请号：US17776436

申请日：2022-03-23

Applicant: PUKYONG NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

Inventor： Hyun Wook KANG

IPC: F21V8/00 ,  A61N5/06 ,  A61N5/067

CPC classification number: G02B6/0008 ,  A61N5/0603 ,  A61N5/067 ,  A61N2005/0609 ,  A61N2005/063

Abstract: The present disclosure relates to an optical transfer device for tissue treatment. An optical transfer device of the present disclosure includes an optical probe having a light divergence part at the longitudinal end thereof, and a coating part configured to surround the optical probe, wherein the coating part includes a light diffusion part formed at the end thereof configured to cover the light divergence part, the light diffusion part having multiple grooves formed thereon.

公开(公告)号：US20240024697A1

公开(公告)日：2024-01-25

申请号：US18229466

申请日：2023-08-02

Applicant: CEDARS-SINAI MEDICAL CENTER

Inventor： Ali Rezaie ,  Mark Pimentel ,  Gil Y. Melmed

IPC: A61N5/06 ,  A61B1/06

CPC classification number: A61N5/0624 ,  A61N5/0603 ,  A61B1/06 ,  A61N5/06 ,  A61B1/0684 ,  A61B1/0638 ,  A61N2005/0608 ,  A61N2005/0661 ,  A61N2005/0667 ,  A61N2005/0602 ,  A61N2005/0609 ,  A61N2005/061 ,  A61N2005/0611 ,  A61N2005/0652

Abstract: The disclosed technology relates to a system for delivering UV-A/B light with a catheter to treat infectious or inflammatory disorders in a patient. While UV light in the UV-C range has traditionally been used to treat skin disorders and for focused ablation of plaques in the arteries and other targeted internal uses, it has not been developed for broader infection, inflammation or neoplasia treatment inside the human body. Here, the inventor(s) developed a system for emission of therapeutic doses of UV light via a catheter, capsule, endoscope, tube or port that can be used to manage internal infections and inflammatory conditions inside a patient.

公开(公告)号：US11826580B2

公开(公告)日：2023-11-28

申请号：US17202878

申请日：2021-03-16

Applicant: The General Hospital Corporation

Inventor： Warren M. Zapol ,  R. Rox Anderson ,  Luca Zazzeron ,  Walfre Franco ,  William A. Farinelli

IPC: A61N5/06 ,  A61M11/00 ,  A61B1/267 ,  A61M15/00 ,  A61N5/067

CPC classification number: A61N5/0603 ,  A61B1/2676 ,  A61M11/00 ,  A61M15/009 ,  A61N5/062 ,  A61M2202/0233 ,  A61N5/067 ,  A61N2005/063 ,  A61N2005/0604 ,  A61N2005/0609 ,  A61N2005/0651 ,  A61N2005/0652 ,  A61N2005/0655 ,  A61N2005/0662 ,  A61N2005/0663 ,  A61M2202/0233 ,  A61M2202/0014

Abstract: Systems and methods are provided for treating or preventing carbon monoxide poisoning. In particular, systems and methods are provided for a phototherapy treatment or prevention system that delivers light radiation to a patient's body to photodissociate carbon monoxide from hemoglobin.

公开(公告)号：US20230347169A1

公开(公告)日：2023-11-02

申请号：US18220362

申请日：2023-07-11

Applicant: OLYMPUS CORPORATION

Inventor： Chikashi OTA

IPC: A61N5/06 ,  G06T7/11

CPC classification number: A61N5/062 ,  G06T7/11 ,  A61N2005/0628 ,  A61N2005/0609 ,  G06T2207/10064 ,  G06T2207/30092 ,  G06T2207/20081 ,  A61N2005/0659

Abstract: A phototherapy device includes: a treatment light emitter configured to emit treatment light for causing a reaction of a drug; a first imager configured to obtain a tissue structure image which is formed using narrow band light applied onto an application position of the treatment light; a second imager configured to obtain a fluorescence image which is formed using excitation light applied onto the application position of the treatment light; a boundary region calculator configured to refer to the tissue structure image to determine a boundary region in which a tissue structure has changed; a fluorescence intensity variation calculator configured to calculate magnitude of variation in fluorescence intensity of the boundary region; and a display image generator configured to generate a display image to be used for displaying the magnitude of variation of the fluorescence intensity.

公开(公告)号：US20230321431A1

公开(公告)日：2023-10-12

申请号：US18167128

申请日：2023-02-10

Applicant: Massachusetts Institute of Technology

Inventor： Polina Olegovna ANIKEEVA ,  Atharva Sahasrabudhe ,  Rajib Mondal

IPC: A61N1/05 ,  A61B5/257 ,  A61N5/06 ,  A61B5/01 ,  A61B5/00 ,  A61L31/02 ,  A61L31/06

CPC classification number: A61N1/0509 ,  A61B5/257 ,  A61N5/0603 ,  A61B5/01 ,  A61B5/4238 ,  A61N5/0622 ,  A61L31/022 ,  A61L31/06 ,  A61B2562/0261 ,  A61B2562/125 ,  A61N2005/0609

Abstract: A soft, stretchable, multifunctional bioelectronic interface can be used to monitor and/or modulate an entire organ, such as a stomach, heart, bladder, or spinal cord. The interface's softness translates to reduced mechanical mismatch with the tissue, and the interface's stretchability reduces interfacial stress with dynamically expanding and contracting organs. The electronics are stretchable thanks in part to liquid-metal conductors sealed within hollow channels of elastomeric fibers embedded in the interface. The liquid metal is largely strain-insensitive, non-toxic, and has a melting point of less than 37° C., so it remains liquid when implanted in a mammalian body. The liquid metal conductors connect microelectronic components, such as micro light-emitting diodes (μLEDs), electrodes, photodiodes, and temperature sensors, to a flexible printed circuit board (fPCB) at one end of the fiber. The interface may include other microelectronic components, such as piezoelectric strain sensors, that are also coupled to the fPCB.

公开(公告)号：US20180256914A1

公开(公告)日：2018-09-13

申请号：US15745827

申请日：2016-07-21

Applicant: KLOX TECHNOLOGIES INC.

Inventor： Lise HÉBERT ,  Michel CIMON ,  David OHAYON ,  Nikolaos LOUPIS ,  Remigio PIERGALLINI

IPC: A61N5/06 ,  A61K41/00

CPC classification number: A61N5/062 ,  A61K9/006 ,  A61K31/352 ,  A61K33/40 ,  A61K41/0057 ,  A61K45/06 ,  A61N2005/0606 ,  A61N2005/0609 ,  A61N2005/0656 ,  A61N2005/0663 ,  Y02A50/473 ,  A61K2300/00

Abstract: The present disclosure provides compositions and methods for treating mucositis associated with treatment-induced neutropenia in a patient. The methods comprise applying a biophotonic composition comprising a fluorescent dye and a carrier to mucosal lesions and subsequently exposing the composition to actinic light.

公开(公告)号：US20170232269A1

公开(公告)日：2017-08-17

申请号：US15583096

申请日：2017-05-01

Applicant: Ojai Retinal Technology, LLC

Inventor： Jeffrey K. Luttrull ,  Benjamin W. L. Margolis ,  David B. Chang

IPC: A61N5/06 ,  A61N1/40 ,  A61N5/02 ,  A61N7/00

CPC classification number: A61N5/0625 ,  A61B18/1815 ,  A61B18/20 ,  A61B18/22 ,  A61B2017/00154 ,  A61B2018/00494 ,  A61B2018/005 ,  A61B2018/00589 ,  A61B2018/00726 ,  A61B2018/00982 ,  A61B2018/00994 ,  A61B2018/20359 ,  A61F9/00817 ,  A61F9/00821 ,  A61F2009/00863 ,  A61N5/025 ,  A61N5/045 ,  A61N5/0603 ,  A61N7/02 ,  A61N2005/0604 ,  A61N2005/0607 ,  A61N2005/0608 ,  A61N2005/0609 ,  A61N2005/063 ,  A61N2005/0659 ,  A61N2005/0662 ,  A61N2005/067 ,  A61N2007/0004 ,  A61N2007/0043

Abstract: A process that provides protective therapy for biological tissues or fluids includes applying a pulsed energy source to a target tissue or a target fluid having a chronic progressive disease or a risk of having a chronic progressive disease to therapeutically or prophylactically treat the target tissue or target fluid. The pulsed energy source has energy parameters selected so as to raise the target tissue or bodily target fluid temperature up to a predetermined temperature for a short period of time to achieve a therapeutic or prophylactic effect, while the average temperature rise of the target tissue or target fluid over a longer period of time is maintained at or below a predetermined level so as not to permanently damage the target tissue or target fluid.

公开(公告)号：US20170143947A1

公开(公告)日：2017-05-25

申请号：US15340408

申请日：2016-11-01

Applicant: COVIDIEN LP

Inventor： REBECCA J. COULSON ,  DARION R. PETERSON ,  JAMES D. ALLEN, IV ,  ANTHONY B. ROSS ,  WILLIAM H. NAU, JR.

IPC: A61M31/00 ,  A61N5/06 ,  A61B18/18 ,  A61F7/00 ,  A61B18/14

CPC classification number: A61M31/00 ,  A61B18/08 ,  A61B18/1485 ,  A61B18/1492 ,  A61B18/1815 ,  A61B2018/00214 ,  A61B2018/00494 ,  A61B2018/1861 ,  A61B2218/002 ,  A61F7/007 ,  A61F2007/0018 ,  A61F2007/0071 ,  A61N5/0603 ,  A61N5/062 ,  A61N5/0625 ,  A61N2005/0608 ,  A61N2005/0609

Abstract: An apparatus for treating inflammatory bowel diseases is provided. The apparatus includes a handle, a shaft extending distally from the handle, and an end effector disposed on a distal end of the shaft. The shaft is configured to be advanced within the colon of a patient. The end effector includes a radiating portion and a nozzle disposed thereon. The radiating portion is configured to emit energy therefrom and the nozzle is configured to emit a fluid therefrom. A method of treating inflammatory bowel diseases is also provided.

公开(公告)号：US20170128404A1

公开(公告)日：2017-05-11

申请号：US14959750

申请日：2015-12-04

Applicant: ENZYCHEM LIFESCIENCES CORPORATION

Inventor： Ki-Young SOHN

IPC: A61K31/231 ,  A61N5/06 ,  A61K9/48 ,  A61K45/06 ,  A61K9/00

CPC classification number: A61K31/231 ,  A61K9/0053 ,  A61K9/4825 ,  A61K9/4858 ,  A61K45/06 ,  A61N5/0603 ,  A61N2005/0606 ,  A61N2005/0609 ,  A61N2005/067

Abstract: The invention provides a pharmaceutical composition for preventing or treating mucositis, for example oral mucositis (e.g., oral ulceration) and gastrointestinal mucositis, comprising a monoacetyldiacylglycerol compound, especially PLAG, and a method of preventing or treating mucositis using the same.

公开(公告)号：US20160361562A1

公开(公告)日：2016-12-15

申请号：US15234299

申请日：2016-08-11

Applicant: St. Jude Medical, Atrial Fibrillation Division, Inc.

Inventor： Karin Järverud ,  Cecilia Emanuelsson ,  Anders Björling ,  Kjell Noren

IPC: A61N5/06 ,  A61N1/05 ,  A61B18/20 ,  A61B5/0408

CPC classification number: A61N5/0613 ,  A61B5/0408 ,  A61B5/05 ,  A61B5/103 ,  A61B18/18 ,  A61B18/20 ,  A61B2018/00577 ,  A61N1/00 ,  A61N1/056 ,  A61N1/30 ,  A61N1/362 ,  A61N1/39 ,  A61N5/06 ,  A61N5/0603 ,  A61N2005/0602 ,  A61N2005/0609 ,  A61N2005/0612 ,  A61N2005/0626 ,  A61N2005/063 ,  A61N2005/0659 ,  A61N2005/0662

Abstract: In response to local or systemic inflammation in a patient, photobiomodulation therapy is applied to a cardiac location to reduce the risk and/or occurrence of cardiac arrhythmia. Once inflammation is identified, photobiomodulation therapy can be applied in any suitable fashion (e.g., via a catheter- or transesophageal probe-mounted photoemitter, via an externally-applied photoemitter, or via photoemitter incorporated into an implantable medical device). Photobiomodulation therapy can also be employed to good advantage in conjunction with non-photobiomodulation therapy (e.g., traditional cardiac rhythm management therapies).

Abstract translation: 响应于患者的局部或全身炎症，将光生物调节治疗应用于心脏位置以降低心律失常的风险和/或发生。 一旦发现炎症，可以以任何合适的方式（例如经由经导管或经食管探针安装的光发射器，经由外部施加的光电探测器，或通过并入可植入医疗装置中的光电发生器）应用光生物调节治疗。 结合非光生物调节治疗（例如传统的心律管理疗法）也可以利用光生物调节治疗来获得良好的优点。